Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Corcept Therapeutics (CORT) over the last 5 years, with Sep 2025 value amounting to $8.2 million.

  • Corcept Therapeutics' Gains from Investment Securities fell 30.03% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.4 million, marking a year-over-year increase of 48.44%. This contributed to the annual value of $60.3 million for FY2024, which is 26.61% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Gains from Investment Securities of $8.2 million as of Q3 2025, which was down 34.40% from $12.4 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Gains from Investment Securities ranged from a high of $45.0 million in Q4 2024 and a low of $1.2 million during Q1 2023.
  • In the last 3 years, Corcept Therapeutics' Gains from Investment Securities had a median value of $8.2 million in 2025 and averaged $13.1 million.
  • Per our database at Business Quant, Corcept Therapeutics' Gains from Investment Securities skyrocketed by 1,500.00% in 2021 and then tumbled by 88.52% in 2022.
  • Over the past 5 years, Corcept Therapeutics' Gains from Investment Securities (Quarterly) stood at $2.5 million in 2021, then spiked by 652.31% to $18.9 million in 2022, then skyrocketed by 108.64% to $39.5 million in 2023, then climbed by 13.83% to $45.0 million in 2024, then slumped by 30.03% to $8.2 million in 2025.
  • Its last three reported values are $8.2 million in Q3 2025, $12.4 million for Q2 2025, and $15.8 million during Q1 2025.